Abstract:Parkinson's disease (PD) is an age-associated neurodegenerative disorder characterized by the death of dopaminergic neurons in the substantia nigra pars compacta. Activation of 5-adenosine monophosphate-activated protein kinase (AMPK) has been suggested to be associated with PD pathogenesis. The aim of the present study was to investigate the effects of the aberrant expression of microRNA-185 (miR-185) in PD. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced in vitro model of PD was generated using the human SH-SY5Y dopaminergic neuroblastoma cell line, in order to examine the potential molecular mechanisms underlying the roles of miR-185 in PD. miR-185 expression was assessed in MPTP-treated SH-SY5Y cells using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, MPTP-treated SH-SY5Y cells were transfected with a miR-185 mimic or scramble miRNA, and flow cytometry was used to evaluate the level of cellular apoptosis. The expression of autophagy markers, including Beclin 1, microtubule-associated protein light chain 3 (LC3) I and LC3II, as well as key molecules involved in the AMPK/mechanistic target of rapamycin (mTOR) signaling pathway, such as phosphorylated (p)-AMPK and p-mTOR, was examined using RT-qPCR and western blot analyses. In addition, SH-SY5Y cells were treated with the AMPK inhibitor, Compound C, and its effects on cellular apoptosis were assessed. The results demonstrated that miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP at concentrations of >100 mu M when compared with untreated controls. Following transfection with a miR-185 mimic, miR-185 expression in SH-SY5Y cells was significantly increased when compared with blank control cells. Notably, miR-185 overexpression was revealed to significantly reduce the MPTP-induced increase in cellular apoptosis. In addition, the expression levels of Beclin 1, LC3I/II, p-AMPK and p-mTOR were significantly upregulated in MPTP-treated SH-SY5Y cells; whereas miR-185 overexpression significantly downregulated the expression of these factors. Furthermore, miR-185 overexpression significantly suppressed apoptosis of SH-SY5Y cells treated with MPTP plus Compound C when compared with the Compound C group. In conclusion, the results of the present study suggest that overexpression of miR-185 may inhibit autophagy and apoptosis of dopaminergic cells in PD potentially via regulation of the AMPK/mTOR signaling pathway. Therefore, AMPK/mTOR-mediated autophagy and apoptotic signaling pathways may be potential novel therapeutic targets for the development of alternative strategies for the treatment of patients with PD.

Overexpression of Mir‑185 Inhibits Autophagy and Apoptosis of Dopaminergic Neurons by Regulating the AMPK/mTOR Signaling Pathway in Parkinson's Disease

Silencing of Mir-497-5p Inhibits Cell Apoptosis and Promotes Autophagy in Parkinson's Disease by Upregulation of FGF2

Suppression Of Microrna-342-3p Increases Glutamate Transporters And Prevents Dopaminergic Neuron Loss Through Activating The Wnt Signaling Pathway Via P21-Activated Kinase 1 In Mice With Parkinson'S Disease

MiR-410 exerts neuroprotective effects in a cellular model of Parkinson's disease induced by 6-hydroxydopamine via inhibiting the PTEN/AKT/mTOR signaling pathway

Lncrna NEAT1 Prompts Autophagy and Apoptosis in MPTP-induced Parkinson's Disease by Impairing Mir-374C-5p

Lncrna NEAT1 Promotes Autophagy of Neurons in Mice by Impairing Mir-107-5p.

miR-214-3p promotes the pathogenesis of Parkinson's disease by inhibiting autophagy

miR-124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK/mTOR pathway in Parkinson's disease.

Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3β/PP2A pathway in Parkinson's disease

miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease

Mir-141-3p Regulates Apoptosis and Mitochondrial Membrane Potential Via Targeting Sirtuin1 in a 1-Methyl-4-phenylpyridinium in Vitro Model of Parkinson's Disease.

MiR-135a-5p and Mst1 regulate MPP + -1 induced apoptosis and autophagy in Parkinson's disease model in vitro

Retracted: Suppression of Microrna‐342‐3p Increases Glutamate Transporters and Prevents Dopaminergic Neuron Loss Through Activating the Wnt Signaling Pathway Via P21‐activated Kinase 1 in Mice with Parkinson's Disease

MiR-30c-5p/ATG5 Axis Regulates the Progression of Parkinson's Disease.

Autophagy‐regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review)

MicroRNA‐190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP‐induced Parkinson's disease mouse model

MiR-124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim.

Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease

Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson's disease

Knockdown of Long Non-Coding RNA AL049437 Mitigates MPP+ -Induced Neuronal Injury in SH-SY5Y Cells Via the Microrna-205-5p/mapk1 Axis.

MicroRNA-409-3p Targeting at ATXN3 Reduces the Apoptosis of Dopamine Neurons Based on the Profile of Mirnas in the Cerebrospinal Fluid of Early Parkinson's Disease